Stifel Reiterates Buy Rating on Seaport Therapeutics (SPTX)

June 9, 2026 3:34 AM

Stifel analyst Paul Matteis reiterated a Buy rating and $30.00 price target on Seaport Therapeutics (NASDAQ: SPTX)The analyst comments: “We're ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found